MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

Search

BioMarin Pharmaceutical Inc

Cerrado

SectorSanidad

52.84 -0.47

Resumen

Variación precio

24h

Actual

Mínimo

52.28

Máximo

53.89

Métricas clave

By Trading Economics

Ingresos

241M

426M

Ventas

80M

825M

P/B

Media del Sector

15.472

36.442

BPA

1.44

Margen de beneficios

51.637

Empleados

3,040

EBITDA

95M

319M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+85.42% upside

Dividendos

By Dow Jones

Próximas Ganancias

28 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-1.5B

10B

Apertura anterior

53.31

Cierre anterior

52.84

Noticias sobre sentimiento de mercado

By Acuity

41%

59%

140 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

16 oct 2025, 21:10 UTC

Principales Movimientos del Mercado

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

16 oct 2025, 19:03 UTC

Adquisiciones, fusiones, absorciones

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

16 oct 2025, 17:58 UTC

Adquisiciones, fusiones, absorciones

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

16 oct 2025, 17:12 UTC

Ganancias

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

16 oct 2025, 17:12 UTC

Adquisiciones, fusiones, absorciones

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

16 oct 2025, 16:59 UTC

Adquisiciones, fusiones, absorciones

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

16 oct 2025, 23:44 UTC

Charlas de Mercado

Gold Climbs Amid Safe-Haven Demand -- Market Talk

16 oct 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

16 oct 2025, 23:42 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 oct 2025, 22:15 UTC

Ganancias

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

16 oct 2025, 22:15 UTC

Ganancias

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

16 oct 2025, 22:15 UTC

Ganancias

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

16 oct 2025, 22:02 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 oct 2025, 22:02 UTC

Charlas de Mercado

Santos Drifts Into 'Oversold Territory' -- Market Talk

16 oct 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Health Care Roundup: Market Talk

16 oct 2025, 20:23 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 oct 2025, 20:23 UTC

Charlas de Mercado

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

16 oct 2025, 20:20 UTC

Ganancias

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

16 oct 2025, 20:08 UTC

Adquisiciones, fusiones, absorciones

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

16 oct 2025, 19:37 UTC

Adquisiciones, fusiones, absorciones

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

16 oct 2025, 19:26 UTC

Ganancias

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 oct 2025, 19:24 UTC

Charlas de Mercado

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

16 oct 2025, 19:23 UTC

Charlas de Mercado

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

16 oct 2025, 19:23 UTC

Ganancias

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 oct 2025, 18:35 UTC

Charlas de Mercado
Ganancias

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

16 oct 2025, 18:31 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 oct 2025, 18:31 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 oct 2025, 18:31 UTC

Charlas de Mercado

Charles Schwab Readies Spot Crypto Trading -- Market Talk

16 oct 2025, 16:57 UTC

Charlas de Mercado

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Comparación entre iguales

Cambio de precio

BioMarin Pharmaceutical Inc previsión

Precio Objetivo

By TipRanks

85.42% repunte

Estimación a 12 Meses

Media 98.44 USD  85.42%

Máximo 122 USD

Mínimo 60 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioMarin Pharmaceutical Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

21 ratings

17

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

59.405 / 62.19Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

140 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat